Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 21, 2021; 27(27): 4383-4394
Published online Jul 21, 2021. doi: 10.3748/wjg.v27.i27.4383
Published online Jul 21, 2021. doi: 10.3748/wjg.v27.i27.4383
Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
Ahmad Hamad, Zachary J Brown, Aslam M Ejaz, Mary Dillhoff, Jordan M Cloyd, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH 43215, United States
Author contributions: Hamad A, Brown ZJ and Cloyd JM drafted the manuscript; all authors critically revised the manuscript.
Conflict-of-interest statement: All authors have no conflict-of-interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jordan M Cloyd, MD, Assistant Professor, Department of Surgery, The Ohio State University Wexner Medical Center, 410 W 10th Ave, N907 Doan Hall, Columbus, OH 43215, United States. jordan.cloyd@osumc.edu
Received: January 28, 2021
Peer-review started: January 28, 2021
First decision: March 29, 2021
Revised: April 12, 2021
Accepted: July 5, 2021
Article in press: July 5, 2021
Published online: July 21, 2021
Peer-review started: January 28, 2021
First decision: March 29, 2021
Revised: April 12, 2021
Accepted: July 5, 2021
Article in press: July 5, 2021
Published online: July 21, 2021
Core Tip
Core Tip: Neoadjuvant therapy (NT) is an increasingly utilized approach that maximizes the receipt of multimodality therapy, improves margin-negative resection rates, and potentially increases survival durations. In the era of personalized medicine, the neoadjuvant period can also be used to emphasize precision oncology. Already, current methods of anatomically staging, molecularly profiling, and monitoring response to therapy can be used to personalize neoadjuvant treatment for localized pancreatic ductal adenocarcinoma (PDAC). In this article, we describe the current evidence for the use of NT and highlight unique opportunities for personalized care in patients with PDAC undergoing NT.